Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2.
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2009
At a glance
- Drugs NAPc2 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nuvelo
- 12 May 2009 Sponsor, affiliate and lead trial centre (ARCA Biopharma), lead investigator (Love T) added as reported by ClinicalTrials.gov.
- 12 May 2009 Primary outcome amended as reported by ClinicalTrials.gov.
- 05 May 2008 The expected completion date for this trial is now 1 Aug 2007, according to ClinicalTrials.gov.